/

Empresas

At

No verificado

Atamyo Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

4 Comunicados de prensa

Ver todos los comunicados de prensa

12/11/2024

Industria

Higiene alimentaria

Salud

Biotecnología

Medicina - Varios

Farmacéutica

IND for ATA-200, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), cleared to proceed by FDA

Fuente

Atamyo Therapeutics

Editor

1.00

0

30/09/2024

Eventos

Ferias y Congresos

Industria

Biotecnología

Técnica

Higiene alimentaria

Salud

Farmacéutica

Ciencia

Tecnología

Medicina - Varios

Atamyo Therapeutics Observes LGMD Awareness Day with Updates on Key Milestones in its Clinical Development of Gene Therapies for Patients Suffering from Limb-Girdle Muscular Dystrophies

Fuente

Atamyo Therapeutics

Editor

1.00

0

16/09/2024

Eventos

Industria

Ciencia

Técnica

Biotecnología

Medicina - Varios

Farmacéutica

Salud

Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe

Fuente

Atamyo Therapeutics

Editor

1.00

0

04/09/2024

Multimedia

Mercado laboral

Voluntariado/Solidaridad/ONGs

Industria

Cardiología

Biotecnología

Farmacéutica

Salud

Asociaciones/Profesionales

Medicina - Varios

The Dion Foundation and Atamyo Therapeutics Announce a Partnership to Expand into the US Atamyo’s Clinical Trial of ATA-200 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5

Fuente

Atamyo Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0